Remternetug (SC)

DRUG2 trials

Sponsors

Eli Lilly and Company, Washington University School of Medicine

Conditions

Alzheimer's DiseaseAlzheimers DiseaseAlzheimers Disease, FamilialDementia

Phase 2

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

RecruitingNCT05552157

Washington University School of MedicineAlzheimers Disease, Alzheimers Disease, Familial, Dementia

Start: 2024-11-22End: 2034-08-30Target: 280Updated: 2026-02-13

Phase 3

A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

Active, not recruitingNCT05463731

Eli Lilly and CompanyAlzheimer's Disease

Start: 2022-08-01End: 2026-03-31Updated: 2025-04-25

Related Papers

Efficacy of therapeutic intervention with NanoBEO to manage agitation and pain in patients suffering from severe dementia: a pilot clinical trial

Frontiers in Pharmacology2024-08-013 citations

Observations on biomarkers in Roche Abeta‐targeting monoclonal antibody trials

Alzheimer s & Dementia2023-12-011 citations